Disease · MONDO_0019100
Comparisons in its trials14
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 14 of 14
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Eculizumab vs Placebo: Participants With An Adjudicated On-trial Relapse | 3 of 96 | 20 of 47 | 143 | NCT01892345 | Trial comparisons |
| Eculizumab vs Placebo: deaths from any cause | 1 of 96 | 0 of 47 | 143 | NCT01892345 | Trial comparisons |
| Eculizumab vs Placebo: serious adverse events | 30 of 96 | 26 of 47 | 143 | NCT01892345 | Trial comparisons |
| Eculizumab/Eculizumab vs Placebo/Eculizumab: Number of Participants With An On-trial Relapse as Determined by The Treating Physician | 8 of 78 | 5 of 41 | 119 | NCT02003144 | Trial comparisons |
| Ravulizumab vs Placebo (ECU-NMO-301): Number of Participants With an Adjudicated On-trial Relapse in the Primary Treatment Period | 0 of 58 | 20 of 47 | 105 | NCT04201262 | Trial comparisons |
| Satralizumab, Then Satralizumab vs Placebo, Then Satralizumab: Number of Participants With Non-Serious Adverse Events of Special Interest in the DB Period | 0 of 63 | 0 of 32 | 95 | NCT02073279 | Trial comparisons |
| Satralizumab, Then Satralizumab vs Placebo, Then Satralizumab: Number of Participants With at Least One Adverse Event in the DB Period | 58 of 63 | 24 of 32 | 95 | NCT02073279 | Trial comparisons |
| Satralizumab, Then Satralizumab vs Placebo, Then Satralizumab: Number of Participants With at Least One Serious Adverse Event in the DB Period | 12 of 63 | 5 of 32 | 95 | NCT02073279 | Trial comparisons |
| Azathioprine vs Rituximab: Number of Participants With Adverse Drug Reactions | 3 of 46 | 4 of 40 | 86 | NCT03002038 | Trial comparisons |
| Azathioprine vs Rituximab: deaths from any cause | 0 of 46 | 0 of 40 | 86 | NCT03002038 | Trial comparisons |
| Azathioprine vs Rituximab: serious adverse events | 1 of 46 | 1 of 40 | 86 | NCT03002038 | Trial comparisons |
| Placebo + Baseline Treatment vs Satralizumab + Baseline Treatment: Number of Participants With Non-Serious Adverse Events of Special Interest in the DB Period | 0 of 42 | 0 of 41 | 83 | NCT02028884 | Trial comparisons |
| Placebo + Baseline Treatment vs Satralizumab + Baseline Treatment: Number of Participants With at Least One Serious Adverse Event in the DB Period | 9 of 42 | 7 of 41 | 83 | NCT02028884 | Trial comparisons |
| Placebo + Baseline Treatment vs Satralizumab + Baseline Treatment: Number of Participants With at Least One Adverse Event in the DB Period | 40 of 42 | 37 of 41 | 83 | NCT02028884 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019100/comparisons